Infection is one of the main causes of death of hospitalized patients. According to the "New England Journal of Medicine" statistics, in the United States alone, the annual incidence of sepsis is 750,000, including 225,000 deaths. The total antibiotic market is about US $ 30 billion, and no real new type of antibiotic has been developed for half a century (Science 2009, 325, 1089). With the extensive use and abuse of traditional antibiotics, a variety of drug-resistant strains have appeared in the clinic, such as "super bacteria" carrying NDM-1 plasmids, methicillin-resistant, vancomycin-causing pathogens, etc. The antibiotics currently in clinical use have no effect on these drug-resistant bacteria, which has become a major threat to human health now and in the future.
In the process of competition with pathogenic bacteria mutations, antimicrobial peptides from various sources in nature have become the hope for people to develop new anti-infective drugs, but the toxicity and low in vivo efficacy have become the bottleneck restricting most antimicrobial peptides for clinical drug development. . Under the leadership of Researcher Zhang Yun and Researcher Li Wenhui, the Key Laboratory of Animal Models and Human Diseases Key Laboratory of Animal Models and Human Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences "Derivatives and their applications" (Patent No .: ZL 2008 1 0058260.9), established an animal model of clinical drug-resistant bacteria infection, and carried out in-depth pharmacodynamic evaluation of Cobra Venom OH-CATH30 antibacterial peptides and derivatives.
Studies have shown that, under the current situation that the widely used antibiotic drug cefoperazone sodium is ineffective, OH-CATH30 and derivatives are within the safe dose range (more than 10 times lower than the toxic dose), and have good systemic and lethal drug-resistant bacterial infections. Therapeutic and protective effects. This result provides a solid in vivo pharmacodynamic basis for the preparation and clinical application of new antimicrobial infection drugs.
Related research papers have been published online in Antimicrobial Agents and Chemotherapy, a famous American journal of pharmacology and pharmacy. The research was supported by the National Major New Drug Creation Project, the National 973 Program Project, and the Fund Committee-Yunnan Joint Fund Project.
Glass Jar,Small Glass Jars,Glass Jars With Lids,Small Glass Jars With Lids
Zhejiang Changxing Hanghua Glass Co., Ltd. , https://www.hanghua-glass.com